Medtronic (NYSE:MDT) Releases FY25 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY25 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $5.40-$5.50 for the period, compared to the consensus estimate of $5.45.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Mizuho upped their price target on shares of Medtronic from $95.00 to $98.00 and gave the stock a buy rating in a report on Wednesday, February 21st. Royal Bank of Canada restated a sector perform rating and issued a $92.00 price objective on shares of Medtronic in a report on Wednesday, February 21st. Oppenheimer increased their price objective on Medtronic from $89.00 to $92.00 and gave the company a market perform rating in a report on Wednesday, February 21st. Finally, Truist Financial increased their price objective on Medtronic from $87.00 to $90.00 and gave the company a hold rating in a report on Wednesday, February 21st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Medtronic presently has an average rating of Hold and a consensus price target of $94.91.

Medtronic Stock Down 2.5 %

Shares of MDT traded down $2.11 on Thursday, reaching $83.65. The company’s stock had a trading volume of 3,199,179 shares, compared to its average volume of 6,080,117. The company has a current ratio of 2.30, a quick ratio of 1.71 and a debt-to-equity ratio of 0.46. Medtronic has a twelve month low of $68.84 and a twelve month high of $91.00. The stock has a market capitalization of $111.07 billion, a PE ratio of 27.31, a PEG ratio of 2.78 and a beta of 0.78. The firm has a fifty day moving average of $82.90 and a 200-day moving average of $82.62.

Medtronic (NYSE:MDT) last posted its earnings results on Thursday, May 23rd. The medical technology company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.01. Medtronic had a net margin of 13.00% and a return on equity of 13.71%. The company had revenue of $8.59 billion for the quarter, compared to analyst estimates of $8.44 billion. During the same quarter in the prior year, the business posted $1.57 EPS. The firm’s revenue was up .5% compared to the same quarter last year. Equities analysts predict that Medtronic will post 5.2 EPS for the current year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 12th. Shareholders of record on Friday, June 28th will be paid a $0.70 dividend. This is a positive change from Medtronic’s previous quarterly dividend of $0.69. This represents a $2.80 annualized dividend and a yield of 3.35%. Medtronic’s dividend payout ratio (DPR) is 87.90%.

Insider Buying and Selling at Medtronic

In other news, EVP Michael Marinaro sold 854 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $83.14, for a total transaction of $71,001.56. Following the completion of the sale, the executive vice president now owns 27,925 shares in the company, valued at approximately $2,321,684.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.30% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.